TICKERNERD
Menu
APVOAPVOHealthcare · Biotechnology

APVO Stock Forecast: Aptevo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$3.95
−3.89% on the day

The 1 Wall Street analysts covering Aptevo Therapeutics, Inc. hold a median 12-month price target of $26 — +545.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.1M
Ticker Nerd rank
10 / 100
Median analyst target
$26
Analysts covering
1
Total return, dividends reinvested
1W
−6.2%
1M
−11.6%
YTD
−58.1%
1Y
−91.8%
From 52W high
−91.5%
From 52W low
+0.3%
$4
$47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APVO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aptevo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
10 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Volatility
63
Accruals
38
Revisions
32
Growth
25
Issuance
17
Quality
17
Value
7
Momentum
2

Size (95): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Aptevo Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

APVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26APVOHigh $30Median $26Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $21Median $26High $30

The green dot is the last close — the median target sits +545.6% from it.

Recent analyst actionsNewest first

Of the 9 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
23 Sept 2024Roth MKMMaintainsBuy$15 → $8.00
13 May 2022Piper SandlerMaintainsOverweight$69 → $20
28 May 2021Roth CapitalMaintainsBuy$64 → $50
25 Nov 2020PiperJaffrayInitiatesOverweight—
25 Nov 2020Roth CapitalInitiatesBuy—
11 Nov 2020Piper SandlerMaintainsOverweight$32 → $69
11 Apr 2018Roth CapitalInitiatesBuy—
9 Sept 2016Piper SandlerInitiatesOverweight—
9 Sept 2016PiperJaffrayInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

APVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Aptevo Therapeutics, Inc. (APVO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 85% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−517.9%

Higher than 2% of US stocks

Return on assets
−118.0%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

APVO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APVOAptevo Therapeutics, Inc.$5.1M
10
GLMDGalmed Pharmaceuticals Ltd.$5.1M
19
HCWBHCW Biologics Inc.$5.1M
54
JUNSJupiter Neurosciences, Inc.$5.1M
13
CLGNCollPlant Biotechnologies Ltd.$5.2M
33
BRTXBioRestorative Therapies, Inc.$5.2M
8
GOVXGeoVax Labs, Inc.$5.0M
33
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APVO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest APVO news & analysis

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Accesswire · 27 July 2026positive

Aptevo Therapeutics announced a new solid tumor strategy and filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to support multiple therapeutic approaches, including radiopharmaceuticals and T-cell engagers.

Why it matters — The patent filing signals a broadening of Aptevo's oncology pipeline through a versatile platform that could open up new partnering opportunities and therapeutic avenues.

FAQ

Frequently asked questions about APVO stock

What is the APVO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Aptevo Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $21 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APVO stock a buy right now?

Of the 1 analysts covering Aptevo Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aptevo Therapeutics, Inc. 10 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APVO?

As at 1 Aug 2026, Aptevo Therapeutics, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will APVO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +545.6% from the last close, and Ticker Nerd's factor model ranks Aptevo Therapeutics, Inc. 10 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APVO stock forecast for 2030?

No analyst covering Aptevo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $30 over the next 12 months.

How has APVO stock performed over the past year?

Aptevo Therapeutics, Inc. returned -91.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aptevo Therapeutics, Inc. do?

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment.

What is the latest news on APVO?

The most recent item we track (Accesswire, 27 July 2026): "Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone". Aptevo Therapeutics announced a new solid tumor strategy and filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to support multiple therapeutic approaches, including radiopharmaceuticals and T-cell engagers.

Company

About Aptevo Therapeutics, Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment. Its lead candidate, mipletamig (CD123 x CD3), is a T-cell engager evaluated in the Phase 1b/2 RAINIER trial for frontline acute myeloid leukemia, combined with standard therapies, showing promising remission rates and a favorable safety profile without cytokine release syndrome in frontline patients. The pipeline includes eight candidates, such as ALG.APV-527 targeting co-stimulatory receptors and tumor antigens, APVO442 (PSMA x CD3) for prostate cancer, APVO455 (Nectin-4 x CD3) for solid tumors, and trispecifics APVO451 and APVO452 that engage tumor antigens, CD3 for T-cell activation, and CD40 for immune modulation. These are generated using the proprietary ADAPTIR and ADAPTIR-FLEX modular protein technology platforms, designed to enhance immune responses against hematologic malignancies and solid tumors. Founded in 2016 and headquartered in Seattle, Washington, Aptevo Therapeutics Inc. operates in the immuno-oncology and hematology sectors, advancing next-generation T-cell engagers to address unmet needs in cancer care.

CEO Mr. Marvin L. White · 37 employees · United States · https://aptevotherapeutics.com